Professor James McCarthy is a Senior Scientist at QIMR Berghofer Medical Research Institute, and an Infectious Diseases Physician at Royal Brisbane and Womens Hospital, both in Brisbane, Australia. His clinical and research training were undertaken in Australia, the United Kingdom, at the University of Maryland and the Laboratory for Parasitic Diseases, National Institutes of Health, Bethesda, MD, before returning to Australia in 1997. A major focus of his research is the development and application of clinical trial systems that entail deliberate infection of human volunteers with malaria parasites by intravenous injection of Plasmodium-infected red blood cells. Volunteers are then studied in the pre-symptomatic period by qPCR to evaluate investigational drugs, vaccines and diagnostics for malaria.Related Projects
- An external quality assurance program for PCR assays to quantify parasitaemia across laboratories in the Asia-Pacific region
- Developing better tools for diagnosing patients and populations at risk of primaquine induced haemolysis
- Developing new diagnostic tests for malaria
- Evaluation and prediction of the effect of combinations of antimalarial drugs
- Identifying better treatments for uncomplicated malaria
- Understanding kinetics of antigens used in rapid diagnostic tests for malaria
- Within-host malaria modelling to improve the treatment of malaria
Related Publications
- A Phase II pilot trial to evaluate safety and efficacy of ferroquine against early P. falciparum in an induced blood-stage malaria infection study
- Characterizing the Blood-Stage Antimalarial Activity of Tafenoquine in Healthy Volunteers Experimentally Infected With Plasmodium falciparum
- Diagnostic performance of a 5-plex malaria immunoassay in regions co-endemic for Plasmodium falciparum, P. vivax, P. knowlesi, P. malariae and P. ovale
- Effect of novel antimalarial ZY-19489 on Plasmodium falciparum viability in a volunteer infection study
- Evaluation of a multiphasic parasite clearance profile after treatment of experimental human infection with the investigational anti-malarial M5717 using segmented mixed effect models
- Heterogeneity of the human immune response to malaria infection and vaccination driven by latent cytomegalovirus infection
- Human antibodies fix complement to inhibit Plasmodium falciparum invasion of erythrocytes and are associated with protection against clinical malaria
- Human IL-10-producing Th1 cells exhibit a molecular signature distinct from Tr1 cells in malaria
- Initiation of gametocytogenesis at very low parasite density in Plasmodium falciparum infection
- Modeling the dynamics of Plasmodium falciparum gametocytes in humans during malaria infection
- Modelling the dynamics of Plasmodium falciparum histidine-rich protein 2 in human malaria to better understand malaria rapid diagnostic test performance
- Plasmodium malariae and ovale genomes provide insights into malaria parasite evolution
- Population Pharmacokinetics and Pharmacodynamics of Chloroquine in a Plasmodium Vivax Volunteer Infection Study
- Positron emission tomography and magnetic resonance imaging of the brain in experimental human malaria, a prospective cohort study
- Quantification of Tafenoquine and 5,6-Orthoquinone Tafenoquine by UHPLC-MS/MS in Blood, Plasma, and Urine, and Application to a Pharmacokinetic Study
- Quantifying primaquine effectiveness and improving adherence: a round table discussion of the APMEN Vivax Working Group
- Safety and Reproducibility of a Clinical Trial System Using Induced Blood Stage Plasmodium vivax Infection and Its Potential as a Model to Evaluate Malaria Transmission
- Safety, pharmacokinetics, and antimalarial activity of the novel triaminopyrimidine ZY-19489: a first-in-human, randomised, placebo-controlled, double-blind, single ascending dose study, pilot food-effect study, and volunteer infection study
- Safety, tolerability, pharmacokinetics, and activity of the novel long-acting antimalarial DSM265: a two-part first-in-human phase 1a/1b randomised study
- Scoping Review of Antimalarial Drug Candidates in Phase I and II Drug Development
- Seeking an optimal dosing regimen for OZ439/DSM265 combination therapy for treating uncomplicated falciparum malaria
- Tafenoquine for the radical cure and prevention of malaria: the importance of testing for G6PD deficiency
- The delayed bloodstream clearance of Plasmodium falciparum parasites after M5717 treatment is attributable to the inability to modify their red blood cell hosts
- Transcriptional profiling and immunophenotyping show sustained activation of blood monocytes in subpatent Plasmodium falciparum infection
- Transmission Blocking Activity of Low-dose Tafenoquine in Healthy Volunteers Experimentally Infected With Plasmodium falciparum
- Within-host modeling of blood-stage malaria